Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Hansa Biopharma AB ( (SE:HNSA) ) has issued an update.
Hansa Biopharma AB announced that CEO Renée Aguiar-Lucander will present at J.P. Morgan’s 44th Annual Healthcare Conference in San Francisco on 14 January 2026, joined by key members of the executive team including the CFO, COO, CMO and CLO. Participation in this high-profile investment conference, alongside one-on-one meeting opportunities arranged through a neighboring corporate access event, underscores Hansa’s efforts to raise its visibility among global healthcare investors and industry leaders as it advances its pipeline of treatments for rare immunological diseases.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK111.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative, life-altering treatments for patients with rare immunological conditions. Built around its proprietary IgG-cleaving enzyme technology platform, the company targets serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. Its portfolio includes imlifidase, a first-in-class IgG antibody-cleaving enzyme that has enabled kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule with redosing potential. Headquartered in Lund, Sweden, Hansa Biopharma operates in Europe and the U.S. and is listed on Nasdaq Stockholm under the ticker HNSA.
Average Trading Volume: 795,627
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.84B
For an in-depth examination of HNSA stock, go to TipRanks’ Overview page.